SCHEDULE 13D/A: RA Capital Management Amends Stake in LENZ Therapeutics, Disclosing 15.1% Beneficial Ownership

RA Capital Management, L.P. and its affiliates have filed an amended Schedule 13D, confirming their beneficial ownership of 15.1% of LENZ Therapeutics, Inc.'s common stock.

Summary

• RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (collectively, the "Reporting Persons") have filed Amendment No. 1 to their Schedule 13D.
• The Reporting Persons collectively beneficially own 4,260,606 shares of LENZ Therapeutics, Inc. common stock.
• This aggregate ownership represents 15.1% of the Issuer's common stock outstanding, based on 28,146,154 shares outstanding as of May 1, 2025.
• The beneficial ownership includes shares directly held by RA Capital Healthcare Fund, L.P. (3,319,339 shares and 54,582 warrants), RA Capital Nexus Fund II, L.P. (694,755 shares and 10,580 warrants), and a separately managed account (164,729 shares and 5,371 warrants).
• Additionally, 9,750 vested stock options and 1,500 stock options scheduled to vest within 60 days are held by Dr. Zach Scheiner for the benefit of RA Capital, with an exercise price of $15.05 per share.
• The filing updates the initial Schedule 13D filed on March 28, 2024.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive. While a 13D/A is primarily factual, the continued significant stake by a reputable healthcare investment firm like RA Capital Management can be viewed favorably by the market, suggesting ongoing confidence in LENZ Therapeutics.

Positives

• A significant institutional investor, RA Capital Management, maintains a substantial 15.1% stake in LENZ Therapeutics, indicating continued confidence in the company.
• The detailed breakdown of ownership across various funds and accounts managed by RA Capital provides transparency regarding their investment structure.

Risks

• The document does not explicitly detail company-specific risks, but the value of the reported holdings is subject to market fluctuations inherent in common stock investments.
• The exercise of stock options and warrants could lead to dilution for existing shareholders, although the impact from the mentioned options is relatively small.

Future Outlook

The document is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the Issuer's future performance or strategic plans.

Industry Context

This filing reflects a significant ownership stake by a specialized healthcare investment fund in a biotechnology company, common in the life sciences sector where institutional investors often take substantial positions to support long-term growth and development.

Legal Proceedings

• None of the Reporting Persons have been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) during the last five years.
• None of the Reporting Persons have been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction resulting in a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws, or finding any violation with respect to such laws, during the last five years.

Stakeholder Impact

• Shareholders: The disclosure provides transparency regarding a significant institutional investor's stake, which can influence investor perception and potentially share price.
• Management: Awareness of a large, active institutional shareholder may influence strategic decisions and corporate governance.

Key Dates

Recommendation

Keywords

LENZ Therapeutics, RA Capital Management, Schedule 13D, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Healthcare Fund, Investment Management, Equity Stake